Cancer incidence and mortality in China, 2022

Datos Bibliográficos

ID23366307
AutoresBingfeng Han (0000-0002-6807-7026, Chinese Academy of Medical Sciences & Peking Union Medical College), Rongshou Zheng (0000-0003-4295-3398, Chinese Academy of Medical Sciences & Peking Union Medical College), Hongmei Zeng (0000-0003-3999-3081, Chinese Academy of Medical Sciences & Peking Union Medical College), Shao-Ming Wang (0000-0003-0420-2833, Chinese Academy of Medical Sciences & Peking Union Medical College), Kexin Sun (0000-0003-1215-7761, Chinese Academy of Medical Sciences & Peking Union Medical College), Ru Chen (0000-0002-2826-2147, Chinese Academy of Medical Sciences & Peking Union Medical College), Li Li (0000-0001-9700-9682, Chinese Academy of Medical Sciences & Peking Union Medical College), Wenqiang Wei (0000-0003-2078-9056, Chinese Academy of Medical Sciences & Peking Union Medical College, autor de correspondencia), Jie He (0000-0002-4324-1125, Chinese Academy of Medical Sciences & Peking Union Medical College, autor de correspondencia)
Año2024
Volumen4
Número1
Páginas47-53
Fecha de publicación2024-03-01
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaJournal of the National Cancer Center (JOURNAL)
Identificadores de la revistaISSN: 2667-0054 • E-ISSN: 2667-0054
EditorialElsevier BV (PUBLISHER)
DOI10.1016/j.jncc.2024.01.006
PMID39036382
OpenAlexW4391671392
IdiomaEN
Citas recibidas72
Referencias citadas17

Background: The National Cancer Center (NCC) of China regularly reports the nationwide statistics on cancer incidence and mortality in China. The International Agency for Research on Cancer (IARC) calculates and publishes the cancer burden of countries around the world every two years. To ensure consistency between the actual surveillance data in China and the data published by IARC, NCC has received approval from the National Health Commission and IARC to simultaneously release the cancer burden data for China in GLOBOCAN 2022. Methods: There were a total of 700 registries reporting high-quality data on cancer incidence and mortality across China in 2018, of which 106 registries with continuous monitoring from 2010 to 2018 were used to establish an age-period-cohort model to simulate the trend of cancer incidence and mortality and to estimate the incidence and mortality in China in 2022. In addition, we analyzed the temporal trends of age-standardized cancer incidence and mortality from 2000 to 2018 using data from 22 continuous cancer registries. Results: It was estimated about 4,824,700 new cancer cases and 2,574,200 new cancer deaths occurred in China in 2022. Cancers of the lung, colon-rectum, thyroid, liver and stomach were the top five cancer types, accounting for 57.42% of new cancer cases. Cancers of the lung, liver, stomach, colon-rectum and esophagus were the five leading causes of cancer deaths, accounting for 67.50% of total cancer deaths. The crude rate and age-standardized incidence rate (ASIR) were 341.75 per 100,000 and 201.61 per 100,000, respectively. The crude mortality rate was 182.34 per 100,000 and the age-standardized mortality rate (ASMR) was 96.47 per 100,000. The ASIR of all cancers combined increased by approximately 1.4% per year during 2000-2018, while the ASMR decreased by approximately 1.3% per year. We observed decreasing trends in ASIR and ASMR for cancers of the esophagus, stomach, and liver, whereas the ASIR increased significantly for cancers of the thyroid, prostate, and cervix. Conclusions: Cancer remains a major public health concern in China, with a cancer profile that reflects the coexistence of developed and developing regions. Sustained implementation of prevention and control measures has resulted in significant reductions in the incidence and mortality rates of certain historically high incidence cancers, such as esophageal, stomach and liver cancers. Adherence to the guidelines of the Healthy China Action Plan and the Cancer Prevention and Control Action Plan, along with continued efforts in comprehensive risk factor control, cancer screening, early diagnosis and treatment, and standardization of diagnostic and therapeutic protocols, are key strategies to effectively mitigate the increasing cancer burden by 2030.

Cancer · Cancer prevention · Cancer registry · Causes of cancer · Colorectal cancer · Incidence (geometry) · Liver cancer · Lung cancer · Mortality rate · Stomach cancer · Thyroid cancer · COVID-19 and healthcare impacts · Demography · Global Cancer Incidence and Screening · Internal Medicine · Medicine · Multiple and Secondary Primary Cancers